Skip to main content

Table 3 Results from clinical trials of PD-1/PD-L1 blockade in B-cell lymphoma

From: Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities

Identifier B-cell lymphoma Antibody, dose Clinical significance References
Anti-PD-1 monoclonal antibody     
NCT02332668 R/R HL (n = 15) Pembrolizumab
2 mg/kg q3w
ORR 60%, CR 13%, PR 47% [99]
NCT03155425 R/R cHL (n = 75) Camrelizumab
200 mg q2w
ORR 76%, CR 28%, PR 48% [100]
NCT02961101 NCT03250962 R/R cHL (n = 86) Camrelizumab
200 mg q3w
or
Decitabine 10 mg/d, d1-5
 + Camrelizumab 200 mg, d8 q3w
Camrelizumab (n = 19): CR 32%
Decitabine + Camrelizumab (n = 42): CR 71%
[101]
NCT03114683 R/R cHL (n = 96) Sintilimab
200 mg q3w
ORR 80.4%, CR 34%, PR 47% [102]
NCT03209973 R/R cHL (n = 70) Tislelizumab
200 mg q3w
ORR 87.1%, CR 62.9%
9 months: PFS 74.5%
[103]
NCT01953692 R/R PMBCL (n = 21) Pembrolizumab
10 mg/kg q2w (n = 10)
200 mg q3w (n = 11)
ORR 48%, CR 33%, PR 14% [104]
NCT02332980 R/R CLL (n = 16)
RT DLBCL (n = 9)
Pembrolizumab
200 mg q3w
ORR 16% (CLL:0%, DLBCL:44%)
CR (DLBCL) 11%, PR (DLBCL) 22%
[105]
Anti-PD-L1 monoclonal antibody     
NCT02401048 R/R FL (n = 27)
R/R DLBCL (n = 34)
Ibrutinib 560 mg qd
 + Durvalumab 10 mg/kg q2w
ORR (all patients) 25%
ORR (FL) 26%
ORR (GCB DLBCL) 13%
ORR (non‐GCB DLBCL) 38%
CR (FL) 4%
CR (GCB DLBCL) 6%
CR (non-GCB DLBCL) 31%
median PFS 4.6 months
median OS 18.1 months
[106]
NCT02541604 HL (n = 9)
NHL (n = 3)
Atezolizumab 15 mg/kg (≤ 18 years)
Atezolizumab 1200 mg (18-29 years)
PR (HL) 22.2%
PR (NHL) 33.3%
[107]